Skip to main content

Table 1 Patient Demographics and Tumor Characteristics

From: A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

Characteristic No. Patients (%)
N = 125
Median age, years (range) 62 (37-84)
Performance status (ECOG)  
0-1 98 (78)
2 21 (17)
3 3 (2)
Unknown 3 (2)
Hormone receptor status  
Positive 75 (60)
Negative 37 (30)
Unknown 13 (10)
Active Treatment setting  
Neoadjuvant 1 (<1)
Adjuvant 1 (<1)
First-line advanced 14 (11)
Second-line advanced 51 (41)
Third-line advanced 35 (28)
Fourth-line advanced or greater 23 (18)
Prior treatments  
Surgery 116 (93)
Hormone therapy 89 (71)
Prior anthracycline therapy 70 (56)
Palliative chemotherapy 81 (65)
Adjuvant chemotherapy 54 (43)
Immunotherapy 8 (6)
Site of metastasis N = 123
Bone 69 (56)
Liver 56 (4)
Lung 44 (36)
Skin 14 (11)
Lymph nodes 13 (11)
Pleura 8 (6)
Brain 7 (6)
Others 26 (21)